In recent years, the pharmaceutical industry has witnessed a transformative shift towards exploring the potential of medical cannabis in addressing diverse health conditions. This pioneering approach stems from the increasing recognition of the therapeutic properties inherent in various cannabis compounds, such as cannabinoids and terpenes. Researchers and pharmaceutical companies alike are delving into rigorous scientific investigations to elucidate the precise mechanisms through which these compounds interact with the endocannabinoid system and other biological pathways. This research-driven exploration has led to promising outcomes, with medical cannabis demonstrating effectiveness in alleviating symptoms and improving the quality of life for patients grappling with conditions ranging from chronic pain, epilepsy, and multiple sclerosis to anxiety disorders and chemotherapy-induced nausea.
Strain development plays a crucial role in the integration of medical cannabis into diverse health conditions. The term “strain” in the context of cannabis refers to a specific genetic variant of the plant that possesses distinct chemical profiles, including varying levels of cannabinoids (like THC and CBD) and terpenes. Strain development is essential because different strains can have unique therapeutic effects, making them more suited for addressing specific health conditions. Researchers are focusing on identifying and developing strains that exhibit targeted medicinal properties, whether that involves creating strains with higher CBD content for conditions like epilepsy or strains with specific terpene profiles that have demonstrated efficacy in managing pain or anxiety. Through selective breeding and genetic manipulation, scientists can enhance the concentration of desired compounds in specific strains, optimising their therapeutic potential.
Bassani Medical’s approach to strain development
At the heart of Bassani Medical’s success lies a strategy of vertical integration, encompassing various facets of the cannabis value chain. Our Research and Development (R&D) process takes centre stage, providing the technological foundation for business development and offering unwavering support to the medical cannabis customer base. To foster groundbreaking strains, we collaborate with local and international research institutions. We have also established our own Strain Research and Development Laboratory, ensuring the cultivation of commercially viable strains designed to address medical treatments. The urgency arises from the alarming rise in opiate-related deaths globally, which necessitates safer alternatives such as cannabis to combat addiction and mitigate its detrimental effects.
The thrust of Bassani Medical’s R&D efforts centres on replacing opiates and conventional mental disease management medications with strains that offer safer and more effective solutions. As a company, we are committed to identifying strains that hold the potential to alleviate pain and anxiety while minimising the adverse effects associated with traditional pharmaceuticals. These precision-crafted strains are developed through meticulous crossbreeding and cultivation, considering factors such as terpene profiles, alkaloid content, and susceptibility to diseases. By meticulously evaluating the commercial viability of strains and prioritising key markers for disease management, Bassani Medical sets the stage for producing transformative medicinal solutions.
To ensure the safety, quality, and consistency of our medical cannabis strains, Bassani Medical employs cutting-edge technology and stringent protocols. With a state-of-the-art, fully automated aeroponics cultivation system and pharmaceutical-grade facilities, we ensure compliance with international safety standards. In the quest for reliability and quality, the prevention of floral diseases and pathogens takes precedence, aligning with their dedication to pharmaceutical principles and regulatory compliance.
While Bassani Medical’s commercial supply of precision-crafted strains is relatively recent, the impact is already resonating among international customers. Notably, our unirradiated products have garnered attention from Israel and Germany, markets known for their strict microbiological specifications. These early successes serve as a testament to the exceptional quality and potential of Bassani’s strains in revolutionising the medical cannabis industry.
Collaboration stands at the heart of Bassani’s journey towards innovation. We work closely with prominent universities in South Africa and the USA, alongside institutions like ARC and CSIR. These partnerships amplify resources, facilitating the identification and development of essential Intellectual Property to benefit society while ensuring collective financial rewards.
While confidentiality agreements limit the disclosure of ongoing clinical trials and research studies, Bassani’s commitment to preclinical trials indicates the potential for profound impacts on the pharmaceutical industry’s landscape. Our continuous commitment to research, development, and strategic partnerships keeps us at the forefront of strain innovation and the medical cannabis realm.
Looking ahead, Bassani Medical’s plans for strain development remain closely guarded due to confidentiality agreements. However, our mission to craft strains with ideal combinations of alkaloids and terpenes targeting pain and anxiety aligns with their overarching vision of ushering in transformative advancements in the medical cannabis sector. As we pursue these goals, we stand poised to shape the future of medical cannabis through innovation, collaboration, and unwavering dedication to improving patients’ lives.
Disclaimer – The information presented in this blog post is intended for informational purposes only and should not be construed as medical advice. Please consult with your healthcare provider before using THC or CBD for medical purposes.
